Gain-of-function mutations in STING drive devastating inflammatory diseases, such as SAVI, and it was therefore reasonable to test whether NO2-FA-induced inhibition of STING could override the genome-encoded hyperactivity of STING in patient-derived cells. This evidence concerns the gene STING1 and STING-associated vasculopathy with onset in infancy.